Статья
ПОЗИЦИИ АНТАГОНИСТА КАЛЬЦИЯ ЛЕРКАНИДИПИНА ПО ДАННЫМ ДОКАЗАТЕЛЬНОЙ КАРДИОЛОГИИ
Представлены данные доказательной кардиологии по результатам зарубежных исследований, в которых изучались эффективность и безопасность современного антагониста кальция (АК) лерканидипина. Результаты представленных исследований демонстрируют устойчивые позиции лерканидипина в современной кардиологии и свидетельствуют, что лечение лерканидипином приводит к выраженному снижению систолического и диастолического артериального давления без существенного влияния на частоту сердечных сокращений. В процессе лечения лерканидипином возникновение периферических отеков — основной побочной реакции, встречающейся при лечении АК, — наблюдается значительно реже, чем при использовании других представителей данного класса препаратов. Дополнительные свойства лерканидипина позволяют рекомендовать применение данного АК при сочетанной патологии.
1. Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. М.: МИА; 2005.
2. Herbette L.G., Vecchiarelli M., Sartani A., Leonardi A. Lercanidipine: Short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Blood Press Suppl 1998;2:10-7.
3. ШпигельА.С.Доказательная медицина. Перспективыдля гомотоксикологии. М.:Арнебия; 2004.
4. Barchielli M.,Dolfini E., Farina P. et al. Clinical pharmacokinetics oflercanidipine.J Cardiovasc Pharmacol 1997;29 Suppl 2:S1–15.
5. Leonardi A., Poggesi E., Taddei C. et al. In vitro calcium antagonist activity of lercanidipine and its enantiomers. J Cardiovasc Pharmacol 1997;29 Suppl 1:S10–S18.
6. Angelico P., Guarneri L., Leonardi A., Testa R. Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J Pharm Pharmacol 1999;51(6): 709–14.
7. Herbette L.G., Vecchiarelli M., Leonardi A. Lercanidipine: short plasma half-life, long du�ration of action. J Cardiovasc Pharmacol 1997;29 Suppl 1:S19–24.
8. Bianchi G., Passoni A., Griffini P.L. Effects of a new calcium antagonist, Rec 15/2375, on cardiac contractility of conscious rabbits. Pharmacol Res 1989;21(2):193-200.
9. De Giorgio L.A., Orlandini F., Malasoma P., Zappa A. Double-blind crossover study of lercanidipine versus amlodipine in the treatment of mild-to-moderate essential hypertension. Curr Ther Res 1999;60(10):511-20.
10. Cafiero M., Giasi M. Long-term (12-month) treatment with lercanidipine in patients with mild to moderate hypertension. J Cardiovasc Pharmacol 1997;29 Suppl 2:S45–49.
11. Barrios V., Navarro A., Esteras A. et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press 2002;11(2):95–100.
12. McClellan K.J., Jarvis B. Lercanidipine. A review of its use in hypertension. Drugs 2000;60(5):1123-40.
13. Testa R., Leonardi A., Tajana A. et al. Lercanidipine (Rec 15/2375): a novel 1,4–dihydropyridine calcium antagonist for hypertension. Cardiovasc Drug Rev 1997;15(3): 187-219.
14. Policicchio D., Magliocca R., Malliani A. Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow-release nifedipine. J Cardiovasc Pharmacol 1997;29 Suppl 2:S31-S35.
15. Rengo F., Romis L. Activity of lercanidipine in double-blind comparison with nitrendipine in combination treatment of patients with resistant essential hypertension.J Cardiovasc Pharmacol 1997;29 Suppl 2:S54-58.
16. Morisco C., Trimarco B. Efficacy and tolerability oflercanidipine in comparison and in combination with atenolol in patients with mild to moderate hypertension in double–blind controlled study. J Cardiovasc Pharmacol 1997;29 Suppl 2:S26-S30.
17. Sangiorgi B.G., Putignano E.,Calcara L., BarbagalloM. Efficacy and tolerability oflercanidipine vs. captopril in patients with mild to moderate hypertension in a double–blind controlled study. J Cardiovasc Pharmacol 1997;29 Suppl 2:S36-S39.
18. Sanchez A., Sayans R., Alvarez J.L. et al. Left ventricular hypertrophy regression after a short antihypertensive treatment with lercanidipine vs. enalapril. Fourth European Meeting on Calcium Antagonists; 1999 Oct 27–29; Amsterdam.
19. Fogari R., Mugellini A., Corradi L. et al. Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients.JHypertens 2000; 18 (Suppl 2):S65.
20. Aranda P., Aranda F.T., Bianchi J.L. et al. Therapeutic efficacy and tolerability of lercanidipine versus candesartan, alone or in combination, in mild-moderate essential hypertensives. J Hypertens 2000;18 Suppl 2:S152.
21. Fogari R., Malamani G.D., Zoppi A. et al. Comparative effect of lercanidipine and nifedipine gastrointestinaltherapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-blind,randomized, parallel-group study. Curr Ther Res 2000;61(12):850-62.
22. Romito R., Pansini M.I., Perticone F. et al. Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the LErcanidipine in ADults (LEAD) study. J Clin Hypertens (Greenwich) 2003;5(4):249-53.
23. Borghi C., Prandin M.G., Dormi A. The use of lercanidipine can improve the individual tolerability to dihydropyridine calcium blockers in hypertensive patients. J Hypertens 2000;18 Suppl 2:S155.
24. Ninci M.A., Magliocca R., Malliani A. Efficacy and tolerability of lercanidipine in elderly patients with mild to moderate hypertension in a placebo-controlled, double-blind study. J Cardiovasc Pharmacol 1997;29 Suppl 2: S40–S44.
25. Omboni S., Zanchetti A. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. Multicenter Study Investigators. J Hypertens 1998;16(12 Pt 1):1831–8.
26. Cherubini A., Fabris F., Ferrari E. et al. Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients:the ELderly and LErcanidipine (ELLE) study.Arch Gerontol Geriatr 2003;37(3):203-12.
27. Белоусов Ю.Б., Леонова М.В. Антагонисты кальция пролонгированного действия и сердечно-сосудистая заболеваемость: новые данные доказательной медицины. Кардиология 2001;(4):87-93.
28. Wu J.R., Liou S.F., Lin S.W. et al. Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1/2 signaling. Pharmacol Res 2009;59(1):48-56.
29. Corsini A., Bonfatti M., Quarato P. et al. Effect of the new calcium antagonist Iercanidipine and its enantiomers on the migration and proliferation of arterial myocytes. J Cardiovasc Pharmacol 1996;28(5):687-94.
30. Grossman E., Messerli F.H. Calcium antagonists. Prog Cardiovasc Dis 2004;47(1): 34-57.
31. Specchia G., Saccaggi S.P., Ghezzi C. Cardiovascular safety of lercanidipine in patients with angina pectoris: a review of six randomized clinical trials. Curr Ther Res 2001;62(1): 3–15.
32. Acanfora D., Gheorgiade M., Rotiroti D. et al. Acute dose-response, double-blind, placebo-controlled pilot study of lercanidipine in patients with angina pectoris. Curr Ther Res 2000;61(5):255-65.
33. Leenen F.H. Dihydropyridine calcium antagonists and sympathetic activity: relevance to cardiovascular morbidity and mortality. In: Epstein M, editor. Calcium Antagonists in Clinical Medicine. 2nd ed. Philadelphia: Hanley & Belfus; 1998. P.527–52.
34. Epstein M. Safety of calcium antagonists as antihypertensive agents: an update. In: Epstein M (ed). Calcium Antagonists in Clinical Medicine. 2nd ed. Philadelphia: Hanley & Belfus; 1998. P.553-71.
35. Sabbatini M., Tomassoni D., Amenta P. Influence of treatment with Ca2+ antagonists on cerebral vasculature of spontaneously hypertensive rats. Mech Ageing Dev 2001;122(8):795-809.
36. Sabbatini M., Leonardi A., Testa R. et al. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000;35(3):775-9.
37. Sabbatini M., Vitaioli L., Baldoni E. et al. Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats. J Pharmacol Exp Ther 2000;294(3):948-54.
38. Dalla Vestra M., Pozza G., Mosca A. et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria:DIAL study (diabete, ipertensione, albuminuria, lercanidipina).Diabetes Nutr Metab 2004;17(5):259-66.
39. Robles N.R., Ocon J., Gomez C.F. et al. Lercanidipine in Patients with Chronic Renal Failure: The ZAFRA study. Ren Fail 2005;27(1):73-80.
40. Cesarone M.R., Incandela L., Ledda A. et al. Pressure and microcirculatory effects of treatment with lercanidipine in hypertensive patients and in vascular patients with hypertension. Angiology 2000;51(8 Pt 2):S53-63.
41. Viviani G.L. Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension. J Cardiovasc Pharmacol 2002;40(1):133-9.